Stock vs Stock Comparison

Stryker Corporation vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–3.

SYK$293.30
LLY$1064.15

🏆 Tale of the Tape

36
SYKLLY
12.9%Profitability (Net Margin)31.7%
35.4xValuation (P/E)39.2x
10.1%Efficiency (ROIC)30.4%
4/9Health (Piotroski F)7/9
4.7Safety (Altman Z)7.8
11.2%Growth (Rev YoY)44.7%
-0.33Risk (Sharpe 1Y)0.61
1.13xBalance Sheet (D/E)3.24x
3.04%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.190
252-Day Correlation
0.163
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricSYKLLY
Market Cap$117.0B$985.4B
P/E Ratio35.4x39.2x
Forward P/E18.2x24.8x
P/B5.21x31.65x
Dividend Yield1.15%0.63%
Beta0.810.48

Quantitative Metrics

MetricSYKLLY
DCF Fair Value$374.97$296.11
DCF Upside+8.0%-68.2%
Piotroski F4/97/9
Altman Z4.727.84
Beneish M-2.62-1.91
FCF Yield3.04%0.68%
Net Debt/EBITDA1.7x1.1x
ROIC10.1%30.4%
WACC9.9%7.8%
ROIC – WACC0.2pp22.5pp
Gross Margin64.0%83.0%
Net Margin12.9%31.7%
Rev Growth YoY11.2%44.7%
Sharpe (1Y)-0.330.61
Max Drawdown 3Y
FCF Payout Ratio30%90%

SYK Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

SYK found in:

IHI11.04%
XLV2.02%
VHT1.76%
XHE1.55%
MGV0.54%
VIG0.49%
DGRW0.45%
SCHV0.45%
VUG0.33%
IWD0.28%
VONV0.25%
ESGV0.23%
SPYV0.22%
SPLG0.22%
SCHX0.21%
IVV0.21%
RSP0.20%
SCHB0.20%
ITOT0.18%
VOO0.18%
VONE0.17%
SPY0.17%
VTI0.16%
SPTM0.16%
URTH0.16%
ACWI0.13%
SPYG0.13%
IWF0.10%
VT0.10%
VONG0.09%
QUS0.04%
ONEO0.03%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

SYK vs LLY: Head-to-Head Analysis

Stryker Corporation (SYK) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, SYK generates a return on invested capital (ROIC) of 10.1% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between SYK and LLY is 0.190, indicating low correlation, making them an effective diversification pair in a portfolio context.

SYK appears in 32 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, SYK or LLY?

Our quantitative analysis compares SYK and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are SYK and LLY correlated?

The 252-day correlation between SYK and LLY is 0.190. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.